BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 36565374)

  • 21. Individual case safety reports--how to determine the onset date of an adverse reaction: a survey.
    Klepper MJ; Edwards B
    Drug Saf; 2011 Apr; 34(4):299-305. PubMed ID: 21417502
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Characterization of Pediatric Reports in the US Food and Drug Administration Adverse Event Reporting System from 2010-2020: A Cross-Sectional Study.
    Phan M; Cheng C; Dang V; Wu E; Muñoz MA
    Ther Innov Regul Sci; 2023 Sep; 57(5):1062-1073. PubMed ID: 37351842
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adverse drug reactions of statins in children and adolescents: a descriptive analysis from VigiBase, the WHO global database of individual case safety reports.
    Conte C; Rousseau V; Vert C; Montastruc F; Montastruc JL; Durrieu G; Olivier P
    Fundam Clin Pharmacol; 2020 Aug; 34(4):518-520. PubMed ID: 32022302
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Suspected adverse drug reactions reported for children worldwide: an exploratory study using VigiBase.
    Star K; Norén GN; Nordin K; Edwards IR
    Drug Saf; 2011 May; 34(5):415-28. PubMed ID: 21513364
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Leveraging Machine Learning to Facilitate Individual Case Causality Assessment of Adverse Drug Reactions.
    Cherkas Y; Ide J; van Stekelenborg J
    Drug Saf; 2022 May; 45(5):571-582. PubMed ID: 35579819
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacovigilance in ophthalmology in Switzerland: an analysis of the most frequently reported ocular adverse drug reactions within the last 25 years.
    Karrer JE; Giovannoni L; Kullak-Ublick GA; Weiler S
    Swiss Med Wkly; 2019 Jun; 149():w20085. PubMed ID: 31256417
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pediatric Drug Safety Surveillance: A 10-Year Analysis of Adverse Drug Reaction Reporting Data in Calabria, Southern Italy.
    Leporini C; De Sarro C; Palleria C; Caccavo I; Piro B; Citraro R; De Sarro G
    Drug Saf; 2022 Nov; 45(11):1381-1402. PubMed ID: 36112324
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Network Analysis for Signal Detection in Spontaneous Adverse Event Reporting Database: Application of Network Weighting Normalization to Characterize Cardiovascular Drug Safety.
    Pétervári M; Benczik B; Balogh OM; Petrovich B; Ágg B; Ferdinandy P
    Drug Saf; 2022 Nov; 45(11):1423-1438. PubMed ID: 36198930
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Retrospective Review of Serious Adverse Drug Reaction Reports in the Nigerian VigiFlow Database from September 2004 to December 2016.
    Ogar CK; Abiola A; Yuah D; Ibrahim A; Oreagba IA; Amadi EC; Adeyeye MC; Oshikoya KA
    Pharmaceut Med; 2019 Apr; 33(2):145-157. PubMed ID: 31933250
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An experimental investigation of masking in the US FDA adverse event reporting system database.
    Wang HW; Hochberg AM; Pearson RK; Hauben M
    Drug Saf; 2010 Dec; 33(12):1117-33. PubMed ID: 21077702
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Social Impact of Suspected Adverse Drug Reactions: An analysis of the Canada Vigilance Spontaneous Reporting Database.
    Castillon G; Salvo F; Moride Y
    Drug Saf; 2019 Jan; 42(1):27-34. PubMed ID: 30121742
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative Assessment of the National Pharmacovigilance Systems in East Africa: Ethiopia, Kenya, Rwanda and Tanzania.
    Barry A; Olsson S; Minzi O; Bienvenu E; Makonnen E; Kamuhabwa A; Oluka M; Guantai A; Bergman U; van Puijenbroek E; Gurumurthy P; Aklillu E
    Drug Saf; 2020 Apr; 43(4):339-350. PubMed ID: 31919794
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Harmonization of individual case safety reports transmission requirements among PAHO reference authorities: a review of their current regulation.
    Lomeli-Silva A; Contreras-Salinas H; Barajas-Virgen MY; Romero-Lopez MS; Rodríguez-Herrera LY
    Ther Adv Drug Saf; 2024; 15():20420986241228119. PubMed ID: 38323190
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Suspected adverse reactions reported for blood, blood components, and blood products in VigiBase.
    Samukange WT; Lu TA; Souverein PC; Gardarsdottir H; Mantel-Teeuwisse AK
    Transfusion; 2023 May; 63(5):982-992. PubMed ID: 36994873
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adverse events following immunisation (AEFI) reports from the Zimbabwe expanded programme on immunisation (ZEPI): an analysis of spontaneous reports in Vigibase® from 1997 to 2017.
    Masuka JT; Khoza S
    BMC Public Health; 2019 Aug; 19(1):1166. PubMed ID: 31455314
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Finding Needles in the Haystack: Clinical Utility Score for Prioritisation (CUSP), an Automated Approach for Identifying Spontaneous Reports with the Highest Clinical Utility.
    Kara V; Powell G; Mahaux O; Jayachandra A; Nyako N; Golds C; Bate A
    Drug Saf; 2023 Sep; 46(9):847-855. PubMed ID: 37535258
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MOdified NARanjo Causality Scale for ICSRs (MONARCSi): A Decision Support Tool for Safety Scientists.
    Comfort S; Dorrell D; Meireis S; Fine J
    Drug Saf; 2018 Nov; 41(11):1073-1085. PubMed ID: 29876835
    [TBL] [Abstract][Full Text] [Related]  

  • 38. International Conference on Harmonisation; Electronic Transmission of Postmarket Individual Case Safety Reports for Drugs and Biologics, Excluding Vaccines; Availability of Food and Drug Administration Regional Implementation Specifications for ICH E2B(R3) Reporting to the Food and Drug Administration Adverse Event Reporting System. Notice of Availability.
    Food and Drug Administration, HHS
    Fed Regist; 2016 Jun; 81(121):40890-1. PubMed ID: 27373012
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Disproportionality Analysis for Pharmacovigilance Signal Detection in Small Databases or Subsets: Recommendations for Limiting False-Positive Associations.
    Caster O; Aoki Y; Gattepaille LM; Grundmark B
    Drug Saf; 2020 May; 43(5):479-487. PubMed ID: 32008183
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Profiling cumulative proportional reporting ratios of drug-induced liver injury in the FDA Adverse Event Reporting System (FAERS) database.
    Brinker AD; Lyndly J; Tonning J; Moeny D; Levine JG; Avigan MI
    Drug Saf; 2013 Dec; 36(12):1169-78. PubMed ID: 24178291
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.